KDH02208
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
SHR-1210, CAS: 1798286-48-2
Obesity paradox role in the immunosuppressive treatment of hepatocellular carcinoma., PMID:40497086
An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report., PMID:40488279
Effectiveness and Safety of TRIPLET Protocol in Patients with Intermediate-Stage Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Refractory., PMID:40480939
Efficacy of transarterial chemoembolization-hepatic arterial infusion chemotherapy combined with targeted therapy and immunotherapy in hepatocellular carcinoma with portal vein tumor thrombosis., PMID:40469916
Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis., PMID:40450144
Rechallenge of anti-PD-1 antibody combined with chemotherapy shows promising efficacy in the treatment of advanced metastatic hepatocellular carcinoma: A case report., PMID:40438874
Immunotherapy combined with chemotherapy: a promising therapeutic approach in the management of colonic squamous cell carcinoma-a case report., PMID:40416862
The Importance of Timing in Immunotherapy: A Systematic Review., PMID:40416194
SMARCA4-deficient undifferentiated thoracic tumor: a case report and literature review., PMID:40400987
Association between reactive cutaneous capillary endothelial proliferation and the efficacy of camrelizumab in esophageal cancer: a retrospective cohort study., PMID:40400922
Camrelizumab in combination with chemotherapy and targeted therapy improves the prognosis in patients with advanced biliary tract cancer: a single-center retrospective clinical study., PMID:40386592
Efficacy and safety of camrelizumab in combination with S-1 plus oxaliplatin sequenced by camrelizumab-based maintenance therapy as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: a retrospective cohort study., PMID:40386583
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost-utility analysis in China and the United States., PMID:40376272
Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: a systematic review and network meta-analysis of randomized controlled trials., PMID:40360867
Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study., PMID:40356893
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma., PMID:40355717
Molecular imaging using 18F-FDG PET/CT and circulating inflammatory and immune indicators to predict pathological response to neoadjuvant camrelizumab plus chemotherapy in resectable stage IIIA-IIIB NSCLC., PMID:40348946
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study., PMID:40346524
Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients., PMID:40346506
Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial., PMID:40346494
Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial., PMID:40335980
Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma., PMID:40331053
Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer., PMID:40313962
Efficacy and safety of immune checkpoint inhibitors for brain metastases of non-small cell lung cancer: a systematic review and network meta-analysis., PMID:40308503
Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells., PMID:40296909
Efficacy, safety and single-cell analysis of neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma: a phase II trial., PMID:40295492
Combining anti-PD-1 antibodies with surufatinib for gastrointestinal neuroendocrine carcinoma: Two cases report and review of literature., PMID:40290678
Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure., PMID:40270608
Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer-Reply., PMID:40266589
Camrelizumab vs Placebo in Patients With Triple-Negative Breast Cancer., PMID:40266585
Pathologically Complete Response to Camrelizumab and Apatinib in Advanced Cervical Cancer with PTEN, PIK3CA, MTOR, and ARID1A Mutations: A Case Report., PMID:40255685
Post-treatment adverse events ranking in targeted immunotherapy for hepatocellular carcinoma: A network meta-analysis based on risk probability assessment., PMID:40252815
Targeting TIME in advanced hepatocellular carcinoma: Mechanisms of drug resistance and treatment strategies., PMID:40250780
Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis., PMID:40247711
Synchronous triple squamous cell carcinomas of the stomach, skin and gingiva with liver, lung, spleen, kidney, bone and brain metastases: A case report., PMID:40242269
Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy., PMID:40226630
Evaluation of the efficacy and safety of neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma., PMID:40223985
Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment., PMID:40195413
A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review., PMID:40190558
Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial., PMID:40184004
SMARCA4-deficient non-small cell lung cancer with metastasis to the sigmoid colon: a case report., PMID:40158181
Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study., PMID:40140192
Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis., PMID:40131366
Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study., PMID:40124372
Correlation Between Treatment-Related Adverse Events and Efficacy of Camrelizumab in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma., PMID:40123149
Long-term survival in a patient with ruptured advanced hepatocellular carcinoma treated with nutritional therapy combined with apatinib and camrelizumab: a case report., PMID:40121613
Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials., PMID:40114962
Case Report: Camrelizumab plus gemcitabine followed by concurrent chemoradiation for HPV-positive and PD-L1-positive tonsillar squamous cell carcinoma., PMID:40109336
Analysis of the effectiveness and safety of lenvatinib/bevacizumab combined with PD-1/PD-L1 inhibitors and GEMOX in the first-line treatment of advanced biliary tract carcinoma., PMID:40106138
Clinical efficacy and safety of transarterial chemoembolization combined with targeted therapy and PD1 inhibitors in patients with advanced liver cancer., PMID:40103872
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
